{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:59:21Z","timestamp":1785499161609,"version":"3.56.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcjd.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:27:47Z","timestamp":1782170867000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like Peptide-1 Receptor Agonist Therapy in Cystic Fibrosis\u2013Related Diabetes: Insights From a Pilot Implementation Program"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9266-9897","authenticated-orcid":false,"given":"Mirna","family":"Gerges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzie","family":"MacDuff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8352-2806","authenticated-orcid":false,"given":"Barna","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-9720","authenticated-orcid":false,"given":"Meredith","family":"Chiasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2026.06.001_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.876842","article-title":"Treatment with LAU-7b complements CFTR modulator therapy by improving lung physiology and normalizing lipid imbalance associated with CF lung disease","volume":"13","author":"Centorame","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcjd.2026.06.001_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001868","article-title":"The \u0394F508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs","volume":"3","author":"Ostedgaard","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcjd.2026.06.001_bib3","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"issue":"Suppl. 2","key":"10.1016\/j.jcjd.2026.06.001_bib4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcjd.2026.06.001_bib5","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/nu14061216","article-title":"The changing landscape of nutrition in cystic fibrosis: The emergence of overweight and obesity","volume":"14","author":"Bailey","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jcjd.2026.06.001_bib7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3945\/ajcn.112.051409","article-title":"Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: A population-based cohort study","volume":"97","author":"Stephenson","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jcjd.2026.06.001_bib8","article-title":"The role of modulators in cystic fibrosis related diabetes","volume":"27","author":"Merjaneh","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.jcjd.2026.06.001_bib9","doi-asserted-by":"crossref","first-page":"E851","DOI":"10.1210\/jc.2010-2460","article-title":"Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis\u2014Effects of pancreatic enzyme supplementation","volume":"96","author":"Kuo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjd.2026.06.001_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcjd.2024.09.001","article-title":"Cystic fibrosis-related diabetes: A first Canadian clinical practice guideline","volume":"49","author":"Coriati","year":"2025","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2026.06.001_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jcf.2024.08.005","article-title":"Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis","volume":"24","author":"Park","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcjd.2026.06.001_bib12","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1210\/clinem\/dgaa167","article-title":"Semaglutide in cystic fibrosis-related diabetes","volume":"105","author":"Gnanapragasam","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjd.2026.06.001_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/dia.2024.0367","article-title":"GLP-1 receptor agonist therapy in cystic fibrosis-related diabetes: A case report","volume":"27","author":"Ayada","year":"2025","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jcjd.2026.06.001_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.aed.2025.03.011","article-title":"Glucagon-like peptide 1 agonist use in an adult with cystic fibrosis-related diabetes and metabolic syndrome","volume":"12","author":"Auth","year":"2025","journal-title":"AACE Endocrinol Diabetes"},{"key":"10.1016\/j.jcjd.2026.06.001_bib15","article-title":"Product Monograph for OZEMPIC\u00ae semaglutide injection including patient medication information","volume":"2022","year":"2018","journal-title":"Rev"},{"key":"10.1016\/j.jcjd.2026.06.001_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.jcjd.2026.06.001_bib17","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.rmed.2005.09.021","article-title":"The effect of massive weight loss on pulmonary function of morbid obese patients","volume":"100","author":"Santana","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.jcjd.2026.06.001_bib18","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1210\/en.2013-1666","article-title":"Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice","volume":"154","author":"Viby","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.jcjd.2026.06.001_bib20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.13544","article-title":"Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial","volume":"21","author":"Geyer","year":"2019","journal-title":"Diabetes Obes Metab"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267126001048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267126001048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:24:37Z","timestamp":1785497077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267126001048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":18,"alternative-id":["S1499267126001048"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2026.06.001","relation":{},"ISSN":["1499-2671"],"issn-type":[{"value":"1499-2671","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like Peptide-1 Receptor Agonist Therapy in Cystic Fibrosis\u2013Related Diabetes: Insights From a Pilot Implementation Program","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Diabetes Canada.","name":"copyright","label":"Copyright"}]}}